Ep204: Troy Wilson on Precision Cancer Drugs and Combos

Episode Summary

Executive Summary: Troy Wilson traces his path from an underachieving student to a serial biotech entrepreneur, emphasizing how mentors, San Diego’s biotech ecosystem, and a willingness to take big scientific swings shaped his career. He details Kura Oncology’s evolution from early discovery work to FDA approval of ziftomenib in AML and the company’s plan to expand into broader leukemia and rational combinations, especially with FTIs and KRAS-pathway drugs.

Main Topics: Troy Wilson’s unconventional path into biotech (Priority: 5/5): Wilson describes a late-blooming academic journey from Palos Verdes to Berkeley, then from physics and biophysics into organic chemistry, law school, and ultimately biotech leadership, highlighting mentors who redirected his trajectory. Mentorship and the Pete Schultz network (Priority: 5/5): Pete Schultz plays a recurring role in Wilson’s career, pushing him toward business, recruiting him into GNF, and helping catalyze Ambrix and later company-building opportunities. Wilson credits the Schultz orbit as formative for scientific ambition and entrepreneurial thinking. From GNF to startup entrepreneurship (Priority: 4/5): Wilson explains how industry exposure at GNF taught him how biotech organizations work and how that experience, plus his interest in emerging modalities, led to co-founding Ambrix and later other startups. San Diego as a biotech ecosystem (Priority: 4/5): He argues San Diego is unusually well-suited for startup formation because of dense talent, scientific mobility, dual-career realities, and a culture that tolerates risk and serial entrepreneurship. Kura Oncology’s origin and thesis (Priority: 5/5): Kura emerged from Araxas/Wellspring work and focused on menin and farnesyl transferase inhibition as underexplored opportunities. Wilson frames the company as built to translate discoveries all the way to market rather than stopping at early clinical proof. Ziftomenib (ComeZifty) approval and AML strategy (Priority: 5/5): Wilson discusses menin inhibition in NPM1-mutant and KMT2A-rearranged AML, the FDA approval of ziftomenib, the role of differentiation therapy, manageable toxicities, and the company’s push into frontline combination studies. FTIs, KRAS, and the logic of combinations (Priority: 4/5): He makes the case that farnesyl transferase inhibitors are due for a comeback because modern molecular tools and combination strategies make them more useful, especially alongside KRAS inhibitors like daraxonrasib.

Key Arguments: Early mentorship and access to strong research environments can redirect an indifferent student into a major scientific career. The best biotech opportunities often emerge from environments where scientists and entrepreneurs can move quickly between institutions, startups, and collaborations. Startups are necessary when promising science is too novel or too cross-functional to thrive inside large-company structures. Kura’s strategy is to build across discovery, development, and commercialization so the company can make better decisions and capture value from breakthrough science. Menin inhibition works by forcing leukemic blasts to differentiate into terminal cells, producing deep responses in genetically defined AML subsets. The company believes menin inhibitors could ultimately treat a much larger fraction of AML than the initial label suggests. Combination therapy is essential in oncology because cancer evolves resistance; ziftomenib and FTI programs are designed to be used with other targeted agents or chemotherapy. FTIs were previously ahead of their time, but the availability of genomics and targeted partners now makes them much more viable. Wilson argues that Kura’s integrated model and culture position it to become one of the few companies to bring more than one drug to market.

Data Points: Kura founded: 2014 - The company was formed from earlier work and later advanced ziftomenib and darlofarnib. FDA approval of ziftomenib: November 2025 - Discussed as full approval in a genetically defined subset of AML. Initial approved population for ziftomenib: NPM1-mutant or KMT2A-rearranged AML - The initial label focused on a small, molecularly defined group of patients. Registrational dataset: 112 patients - Single-arm trial supporting approval in relapsed/refractory NPM1-mutant AML. Frontline phase 3 trials underway: 2 global studies - Kura and partner Kura Kirin are enrolling broader frontline leukemia populations. Frontline enrollment: about 1,300 patients - Combined size of the ongoing phase 3 programs in frontline leukemia. Potential U.S. peak revenue: up to $3 billion per year - Wilson’s estimate for ziftomenib if frontline development succeeds. Company headcount: about 280 - Kura’s current scale across San Diego, Boston, and remote workers. Avidity founding year: 2012 - Wilson co-founded Avidity before its later growth and acquisition. Avidity acquisition value: about $11 billion - Mentioned as Novartis’s acquisition of the company. Rare AML subset prevalence: ~5% of AML - KMT2A rearrangements were described as approximately five percent of AML. Combination therapy duration example: up to 2 years - Some frontline patients on ziftomenib-containing regimens remained disease-free for two years. FTI potency improvement: 1,000x better - Wilson described darlofarnib as roughly 1000-fold better than first-generation tipifarnib. KRAS inhibitor landscape: ~50 KRAS inhibitors in development - Wilson used this to explain why adjacent combination strategies matter. Targeted therapy outcome example: 13 months overall survival - He cited Revolution Medicines’ pancreatic cancer data as improved but still insufficient.

Pivotal Quotes: "If you ask our team, they will tell you we prioritize patients. It's not something we say, it's something we do every day." — Troy Wilson: On Kura’s culture and how the company makes decisions around trials, access, and execution. "What I think you're saying with Darlie Farnab is that it hits, it basically blocks those escape routes for the tumor." — Luke Timmerman: Summarizing the rationale for combining an FTI with KRAS-pathway inhibition. "Why not? Right? Why risk it? Particularly if it has no other side effects." — Troy Wilson: On the possibility of patients staying on ziftomenib long-term after response.

Implications: The interview suggests AML treatment is moving toward molecularly defined, combination-based chronic management, and that integrated biotech companies with deep science and execution discipline can still create major value from long-debated targets like menin and FTIs.